International Edition
World Markets FX Policy

Monday, 26 October 2026

Private Trade News

Global markets, trading & world business — for professional traders

Markets

Aptevo Therapeutics Inc. Reports 21% of Frontline AML Patients in Mipletamig Combination Study Advanced to Stem Cell Transplant

Private Trade News trader edition (2026-10-26): Aptevo Therapeutics Inc. Reports 21% of Frontline AML Patients in Mipletamig Combination Study Advanced to Stem Cell Transplant Aptevo Therapeutics Inc.… Primary source: original at Nasdaq (nasdaq.com).

· Nasdaq

Aptevo Therapeutics Inc. Reports 21% of Frontline AML Patients in Mipletamig Combination Study Advanced to Stem Cell Transplant

Aptevo Therapeutics Inc. announced that ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allogeneic stem cell transplant following treatment with mipletamig in combination with venetoclax and azacitidine. Specifically, ten of 47 (21%) evaluable fron

Read at source

Read also